Clive Harmer - Concepedia

Author

Clive Harmer

Also Known As

C Harmer, C L Harmer, C. Harmer, C. L. HARMER, C. L. Harmer, C.L. Harmer, CL Harmer, CLIVE L. HARMER, Clive Harmer, Clive L Harmer

185

Publications

7.6K

Citations

H-Index

Concepts

All Affiliations

Royal Marsden Hospital Royal Marsden NHS Foundation Trust Institute of Cancer Research

About

Clive Harmer is an author at Royal Marsden Hospital specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	40	66	4.1K
2	Health Sciences	21	29	1.8K
3	Engineering	3	3	101
4	Public Health	1	1	22
5	Endocrinology	1	1	150

Clive Harmer

Publications

6.2K

Citations

H-Index

Page 1

	Year	Citations
Ablation with Low-Dose Radioiodine and Thyrotropin Alfa in Thyroid Cancer Ujjal K. Mallick, Clive Harmer, B. Yap, New England Journal of Medicine	2012	606
Radioiodine treatment of metastatic thyroid carcinoma: the Royal Marsden Hospital experience Aaron Brown, W P Greening, V. R. McCready, British Journal of Radiology Case RecordsDistant SpreadMetastatic Thyroid CarcinomaMedicineRadionuclide Therapy	1984	210
Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome M. Haq, Clive Harmer Clinical Endocrinology	2005	183
Head and neck sarcomas: prognostic factors and implications for treatment Cyril Fisher, Roger A’Hern, Martin Robinson, British Journal of Cancer MedicineNeck SarcomasPathologyNeck PathologyHead And Neck Cancer	1993	174
Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial. Ian E. Smith, Adrian L. Harris, Myfanwy Morgan, BMJ Breast OncologyCancer ManagementRandomized Cross-over TrialPharmacotherapyAdvanced Breast Carcinoma	1981	152
Testicular dose and fertility in men following I<sup>131</sup> therapy for thyroid cancer Stephen Hyer, L. Vini, Mary E. O'Connell, Clinical Endocrinology	2002	151
Hormone replacement therapy and survival after surgery for ovarian cancer. Rosalind A. Eeles, Seang Lin Tan, E. Wiltshaw, BMJ Surgical OncologyCancer ManagementGynecologyRelative RiskSurgery	1991	150
Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial Hakim‐Moulay Dehbi, Ujjal K. Mallick, Jonathan Wadsley, The Lancet Diabetes & Endocrinology	2018	136
Improvements in target coverage and reduced spinal cord irradiation using intensity-modulated radiotherapy (IMRT) in patients with carcinoma of the thyroid gland Christopher M. Nutting, D. Convery, Vivian P. Cosgrove, Radiotherapy and Oncology Adaptive RadiotherapyRadiation MedicineRadiation TherapyMedicineTarget Coverage	2001	132
Salivary Gland Toxicity after Radioiodine Therapy for Thyroid Cancer Stephen Hyer, Anthony Kong, B. Pratt, Clinical Oncology MedicineThyroid DiseaseThyroid CancerRadiopharmaceutical TherapyToxicology	2006	131

Page 1